ProBioGen, a CDMO of solutions and services for biopharmaceutical development, has partnered with Mapp Biopharmaceutical Inc. to develop a cell line for an afucosylated antibody targeting Marburg virus (MARV) infection. This collaborative effort will leverage ProBioGen’s GlymaxX technology to enhance the therapeutic potential of the antibody by adjusting the afucosylation levels.
 
Under the terms of the agreement, ProBioGen will contribute its expertise in cell line development including its proprietary DirectedLuck transposase system and GlymaxX technology to enhance antibody-dependent cellular cytotoxicity (ADCC) of the molecule.

Targeting MARV Infection

This collaboration aims to address the urgent need for advanced therapies against MARV infections, a severe and often fatal illness caused by the Marburg virus.
 
“We are excited to collaborate with Mapp Biopharmaceutical Inc. in the development of a cell line for an afucosylated antibody targeting MARV infection, utilizing our GlymaxX technology,” said Volker Sandig, CSO at ProBioGen. “This again confirms the versatility of our technology which is broadly used for cancer therapeutics but can also make a meaningful impact in the fight against life-threatening infections.”
 
Marburg virus poses a significant public health threat, and the development of an antibody represents a promising avenue for therapeutic intervention. By reducing fucose levels in the antibody’s glycan structure, GlymaxX technology enhances its effector functions, potentially improving the overall efficacy of the antibody in combating MARV infection.
 
“We are pleased to partner with ProBioGen to develop a cell line to produce our afucosylated antibody to treat MARV infection,” commented Dr. Ronald Aimes, VP, Development – Marburg at Mapp Biopharmaceutical Inc. “This collaboration exemplifies our shared commitment to addressing unmet medical needs and underscores the potential of combining our capabilities to deliver innovative and impactful biopharmaceutical solutions for infectious diseases.”
 
The collaboration between ProBioGen and Mapp Biopharmaceutical Inc. represents a milestone in the pursuit of novel therapies against infectious diseases. Both companies remain dedicated to advancing biopharmaceutical development and contributing to the global effort to improve healthcare outcomes.